Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 8/20 | 0.41 |
| ▸ | MAT2A | P31153 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.36 |
| ▸ | CDK1 | P06493 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6538962 | 0.89 | PPARD (0.39) | PPARDMAT2ATP53POLBHRH3 | |
| SCHEMBL6539329 | 0.88 | PPARD (0.41) | PPARD | |
| SCHEMBL6208111 | 0.85 | ESR2 (0.47) | PPARDTP53POLBHRH3MEN1 | |
| SCHEMBL6539395 | 0.85 | POLB (0.41) | PPARDMAT2ATP53POLB | |
| SCHEMBL13157625 | 0.84 | LMNA (0.42) | PPARDTP53POLB | |
| SCHEMBL13157587 | 0.84 | LMNA (0.42) | PPARDTP53POLB | |
| SCHEMBL6538890 | 0.84 | MTNR1A (0.44) | PPARDTP53POLBMEN1KMT2A | |
| SCHEMBL6539564 | 0.84 | NPSR1 (0.50) | PPARDPOLBMEN1KMT2A | |
| SCHEMBL6539829 | 0.83 | POLB (0.43) | PPARDTP53POLBCDK1MEN1 | |
| SCHEMBL6539414 | 0.81 | PPARD (0.43) | PPARDPTGS2POLBCHEK1CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040157891-A1 | Inhibitor of cox | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157891-A1 | Inhibitor of cox | PTGS1, PTGS2, PTGES2 | PPARD 1747/4885MAT2A 1224/4885PTGS2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.